Opinion
Video
Switching to Biosimilars for the Management of Psoriasis
Author(s):
An expert discusses how examining biosimilars in trials ensures safety, efficacy, and interchangeability, key for clinical adoption. The phase 3 study’s week 52 results confirmed consistent pharmacokinetics, efficacy, and safety. As confidence grows, biosimilars will expand treatment access for psoriasis patients.
Video content above is prompted by the following:
- Why is it so critical to examine biosimilars in clinical trials?
- Discuss the importance of interchangeability and whether it is implemented in your clinical practice.
- What were the study methods for this interchangeability study?
- What were the key results seen in terms of pharmacokinetics, efficacy, and safety profile?
- How do you see the use of biosimilars evolving in the future for patients with psoriasis?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
